Ironwood Pharmaceuticals (NASDAQ: IRWD) reported disappointing third-quarter earnings results on Tuesday, sending its shares sharply lower in pre-market trading. The biopharmaceutical company's adjusted earnings per share missed Wall Street's expectations by a wide margin, overshadowing a slight revenue beat.
For the quarter ended September 30, 2024, Ironwood posted adjusted earnings of $0.02 per share, falling significantly short of the consensus estimate of $0.08 per share. This represented an 83.3% decline compared to the prior-year quarter.
Revenue for the quarter came in at $91.6 million, narrowly surpassing analysts' projections of $91.2 million but marking a 19.5% decrease from the same period last year. The decline was primarily driven by lower sales of Ironwood's flagship drug LINZESS due to pricing pressures in the U.S. market.
Despite the disappointing quarterly performance, Ironwood maintained its full-year 2024 financial guidance, projecting total revenue in the range of $350 million to $375 million and adjusted EBITDA above $75 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。